Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

A. Luetkemeyer,S. Rosenkranz,Darlene Lu,B. Grinsztejn,Jorge Sanchez,Michael Ssemmanda,I. Sanne,H. McIlleron,D. Havlir,D. Haas
DOI: https://doi.org/10.1093/cid/civ155
IF: 20.999
2015-06-15
Clinical Infectious Diseases
Abstract:In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
What problem does this paper attempt to address?